LEPTON ANNOUNCED THAT IT COMPLETED THE FILING FOR AN ADDITIONAL PATENT APPLICATION WHICH DESCRIBES AND CLAIMS EXTENDING THE USAGE OF ITS CASTLING BREAKTHROUGH TECHNOLOGIES FOR ENHANCING THE THERAPEUTIC EFFICACY OF IMMUNE CELLS DERIVED FROM iPSC CELLS The patent application, U.S. Provisional Patent Application No. 63/520,949, is entitled METHODS FOR ENHANCING THERAPEUTIC EFFICACY OF ISOLATED CELLS...

License allows Lepton, with their proprietary Castling Technology, to develop and commercialize products and services using CRISPR/Cas9 technology Dublin, Ireland and Zichron Yakov, Israel, 26 July 2022: ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with Lepton Pharmaceuticals LTD (‘Lepton”). This is a non-exclusive licensing agreement granting Lepton access to the...

Lepton is pleased to announce that the Company has signed a consulting agreement with Dr. Elena Sotillo, Senior Research Scientist at the lab of Prof. Crystal Mackall, the Ernest and Amelia Gallo Family Professor of Pediatrics and Medicine at Stanford University and founding director of the Center for Cancer Cell Therapy, Stanford Cancer Institute, Palo...

Lepton is proud to announce that Prof. Malcolm K Brenner, M.D., Ph.D. at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX US and  Fayez Sarofim Distinguished Service Professor at Baylor College of Medicine in the Departments of Medicine, Pediatrics, and Human and Molecular Genetics. agreed to consult to Lepton for...

Lepton is pleased to announce that the Company has signed a consulting agreement with Dr. Paz Einat for consulting services in the field of development of Lepton’s developmental pharmaceutical therapeutics based on siRNA and/or miRNA.  Dr. Paz Einat is an expert in molecular biology in general (vectorology, gene expression, genomics, directed evolution and more) and...

Lepton announces filing of a PCT application covering its proprietary breakthrough Castling Technology Lepton Pharmaceuticals announces that it has filed a PCT application with the US Patent Office entitled METHODS FOR ENHANCING THERAPEUTIC EFFICACY OF ISOLATED CELLS FOR CELL THERAPY. The Patent application covers Lepton’s breakthrough Castling technology, which is, in essence, the manipulation/engineering of...

Lepton and the Medical Center University of Freiburg sign a Sponsored Research Agreement to use miRNA Castling Technology to improve CAR T cells persistence and cytotoxicity for treatment of Cancer Lepton Pharmaceuticals announces that it signed a sponsored research agreement with the Institute for Transfusion Medicine and Gene Therapy (ITG), Medical Center – University of...

Lepton Pharmaceutical announces that on February 10, 2021 it entered into a Master Service Agreement with Axolabs GMBH, Kulmbach Germany. Pursuant to the agreement, Axolabs shall provide to Lepton Pharmaceutical chemical laboratory services for Lepton’s pipeline in development by directly targeting immunological drivers of diseases. Axolabs is a leading custom research organization providing high-end preclinical...